Matches in Wikidata for { <http://www.wikidata.org/entity/Q80215607> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- Q80215607 description "artículu científicu espublizáu n'abril de 2007" @default.
- Q80215607 description "im April 2007 veröffentlichter wissenschaftlicher Artikel" @default.
- Q80215607 description "scientific article published on 26 April 2007" @default.
- Q80215607 description "wetenschappelijk artikel" @default.
- Q80215607 description "наукова стаття, опублікована у квітні 2007" @default.
- Q80215607 name "Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma" @default.
- Q80215607 name "Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma" @default.
- Q80215607 type Item @default.
- Q80215607 label "Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma" @default.
- Q80215607 label "Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma" @default.
- Q80215607 prefLabel "Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma" @default.
- Q80215607 prefLabel "Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma" @default.
- Q80215607 P1433 Q80215607-9A911165-7FBF-41E7-A2E9-44090A7C00EB @default.
- Q80215607 P1476 Q80215607-C80CA822-45DA-40AD-82B1-6F59FF078EF7 @default.
- Q80215607 P2093 Q80215607-27105291-5196-4EDC-873B-A4F6334C0EF2 @default.
- Q80215607 P2093 Q80215607-2913A160-612C-469E-B870-4D0B8DC6BF45 @default.
- Q80215607 P2093 Q80215607-459D0DC5-A59A-4062-9272-6BA16CBBE4F1 @default.
- Q80215607 P2093 Q80215607-73D5FB5E-DBAE-4603-B768-449AB6502148 @default.
- Q80215607 P2093 Q80215607-A0831023-06CE-4C2F-9459-4EFDC3E3444B @default.
- Q80215607 P2860 Q80215607-09F71362-FD9D-4A20-BC56-164B229F5C49 @default.
- Q80215607 P2860 Q80215607-11D06EC5-5550-4833-85B7-6095D65774DB @default.
- Q80215607 P2860 Q80215607-1D180054-4EC2-49F8-BDAD-458A5AD21920 @default.
- Q80215607 P2860 Q80215607-2C27C998-B73A-48A9-AA98-FF3841721C65 @default.
- Q80215607 P2860 Q80215607-6A6B4DA3-3623-41F1-B414-A6B869384A22 @default.
- Q80215607 P2860 Q80215607-70298A67-5F63-4866-ABCF-4D6CD070480A @default.
- Q80215607 P2860 Q80215607-864F5AAD-BD8E-4651-9ED4-9D69181DBF81 @default.
- Q80215607 P2860 Q80215607-8E2290FE-4D36-4240-A567-12779F459B56 @default.
- Q80215607 P2860 Q80215607-93C2805B-860E-4BB5-8B1C-2195AA82C19C @default.
- Q80215607 P2860 Q80215607-988E888D-E77A-49D3-B7B4-82124CCB1F06 @default.
- Q80215607 P2860 Q80215607-AAFB2402-D8EC-46AB-A6DA-6E0668241082 @default.
- Q80215607 P2860 Q80215607-E8F0FEC9-9B4F-4DAE-9E9F-A5A62D9BE3E5 @default.
- Q80215607 P2860 Q80215607-ECABF560-058D-4932-92EA-6E19826B2DF6 @default.
- Q80215607 P2888 Q80215607-382FC0DB-50F7-475B-A0F8-68EB5F98FEE7 @default.
- Q80215607 P304 Q80215607-B7F38470-B449-4383-9BBC-3A3233BB4FF7 @default.
- Q80215607 P31 Q80215607-105DF35A-34FC-482E-A163-EF38B559912C @default.
- Q80215607 P356 Q80215607-515B72B6-988D-42DF-893C-2C7054A1A734 @default.
- Q80215607 P433 Q80215607-B5FA3924-E87D-4B6F-BA5B-6A9D8B83F87B @default.
- Q80215607 P478 Q80215607-1C2B0B3A-16FC-4CB3-82CE-852224B4B5B0 @default.
- Q80215607 P50 Q80215607-491CB6AE-7110-4EA0-868C-48D09845D70F @default.
- Q80215607 P577 Q80215607-3E9BEB72-DD84-469C-A0B4-E64F9DA9D806 @default.
- Q80215607 P698 Q80215607-4F76A1A9-7C49-4618-8994-9BD2A5ABED91 @default.
- Q80215607 P921 Q80215607-1510DFE9-4DAA-48F1-AEFA-268C7DAE311B @default.
- Q80215607 P921 Q80215607-242BEA36-04F8-4757-A968-20E740B9631A @default.
- Q80215607 P921 Q80215607-424B3EA6-29A3-43D7-A927-475242D2C5FB @default.
- Q80215607 P921 Q80215607-7D349632-E6D1-4136-B439-524F2E9295DF @default.
- Q80215607 P356 S00432-007-0210-4 @default.
- Q80215607 P698 17458562 @default.
- Q80215607 P1433 Q2081599 @default.
- Q80215607 P1476 "Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma" @default.
- Q80215607 P2093 "A Schneider" @default.
- Q80215607 P2093 "H Oelschläger" @default.
- Q80215607 P2093 "M Fedders" @default.
- Q80215607 P2093 "O Camara" @default.
- Q80215607 P2093 "R Kath" @default.
- Q80215607 P2860 Q33331105 @default.
- Q80215607 P2860 Q33332312 @default.
- Q80215607 P2860 Q33581197 @default.
- Q80215607 P2860 Q33603239 @default.
- Q80215607 P2860 Q33845845 @default.
- Q80215607 P2860 Q34346205 @default.
- Q80215607 P2860 Q40673230 @default.
- Q80215607 P2860 Q43675453 @default.
- Q80215607 P2860 Q53608876 @default.
- Q80215607 P2860 Q53676269 @default.
- Q80215607 P2860 Q53829553 @default.
- Q80215607 P2860 Q54039002 @default.
- Q80215607 P2860 Q73443071 @default.
- Q80215607 P2888 s00432-007-0210-4 @default.
- Q80215607 P304 "619-625" @default.
- Q80215607 P31 Q13442814 @default.
- Q80215607 P356 "10.1007/S00432-007-0210-4" @default.
- Q80215607 P433 "9" @default.
- Q80215607 P478 "133" @default.
- Q80215607 P50 Q77697690 @default.
- Q80215607 P577 "2007-04-26T00:00:00Z" @default.
- Q80215607 P698 "17458562" @default.
- Q80215607 P921 Q18556145 @default.
- Q80215607 P921 Q18936 @default.
- Q80215607 P921 Q423762 @default.
- Q80215607 P921 Q974135 @default.